Domestic companies will have delay on launching blockbuster ‘Trajenta’ generics

Domestic generic companies failed in challenging the substance patent of antidiabetic ‘Trajenta.’

In the past, domestic companies won nullification suits for its crystalline and formulation patents which are expiring the latest.

Its crystalline and formulation patents are expected to be expired on April 30, 2027, and the substance patent is expiring on August 18, 2023. Thus, domestic drug com...